Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition
JAMA · 2024
DOI: 10.1001/jama.2024.0924 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Ameet Sarpatwari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics, and Law, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Drugs, Generic, Prescription Drugs, Risk Evaluation and Mitigation, Patents as Topic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study identifies the prevalence of patents on risk evaluation and mitigation strategies and their association with delaying generic competition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program on Regulation, Therapeutics, and Law, Brigham and Women's Hospital, Boston, Massachusetts.
- West Virginia University College of Law, Morgantown.
Zitieren
APA
Sarpatwari, A., Kohli, S., Tu, S. S., & Kesselheim, A. S. (2024). Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition. JAMA. https://doi.org/10.1001/jama.2024.0924
Vancouver
Sarpatwari A, Kohli S, Tu SS, Kesselheim AS. Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition. JAMA. 2024. doi:10.1001/jama.2024.0924
BibTeX
@article{Sarpatwari2024,
author = {Sarpatwari, Ameet and Kohli, Sajeev and Tu, S Sean and Kesselheim, Aaron S},
title = {Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.0924}
}
EUVIMED